Association between cannabis use and symptom dimensions in schizophrenia spectrum disorders: an individual participant data meta on 3053 individuals

Background The association between cannabis use and positive symptoms in schizophrenia spectrum disorders is well documented, especially via meta-analyses. Yet, findings are inconsistent regarding negative symptoms, while other dimensions such as disorganization, depression, and excitement, have not...

Descripción completa

Detalles Bibliográficos
Autores: Argote M, Sescousse G, Brunelin J, Baudin G, Schaub MP, Rabin R, Schnell T, Ringen PA, Andreassen OA, Addington JM, Brambilla P, Delvecchio G, Bechdolf A, Wobrock T, Schneider-Axmann T, Herzig D, Mohr C, Vila-Badia R, Rodie JU, Mallet J, Ricci V, Martinotti G, Knížková K, Rodriguez M, Cookey J, Tibbo P, Scheffler F, Asmal L, Garcia-Rizo C, Amoretti S, Huber C, Thibeau H, Kline E, Fakra E, Jardri R, Nourredine M, Rolland B
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2023
País:España
Institución:Fundació Sant Joan de Déu
Repositorio:r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
OAI Identifier:oai:fsjd.fundanetsuite.com:p24623
Acceso en línea:https://fsjd.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=24623
Access Level:acceso abierto
Palabra clave:Cannabis
Schizophrenia
PANSS
Individual participant data
Symptom dimensions
Meta-analysis
id ES_0c11f1ccf8e6efa9be897445b22e6d32
oai_identifier_str oai:fsjd.fundanetsuite.com:p24623
network_acronym_str ES
network_name_str España
repository_id_str
spelling Association between cannabis use and symptom dimensions in schizophrenia spectrum disorders: an individual participant data meta on 3053 individualsArgote MSescousse GBrunelin JBaudin GSchaub MPRabin RSchnell TRingen PAAndreassen OAAddington JMBrambilla PDelvecchio GBechdolf AWobrock TSchneider-Axmann THerzig DMohr CVila-Badia RRodie JUMallet JRicci VMartinotti GKnížková KRodriguez MCookey JTibbo PScheffler FAsmal LGarcia-Rizo CAmoretti SHuber CThibeau HKline EFakra EJardri RNourredine MRolland BCannabisSchizophreniaPANSSIndividual participant dataSymptom dimensionsMeta-analysisBackground The association between cannabis use and positive symptoms in schizophrenia spectrum disorders is well documented, especially via meta-analyses. Yet, findings are inconsistent regarding negative symptoms, while other dimensions such as disorganization, depression, and excitement, have not been investigated. In addition, meta-analyses use aggregated data discarding important confounding variables which is a source of bias.Methods PubMed, ScienceDirect and PsycINFO were used to search for publications from inception to September 27, 2022. We contacted the authors of relevant studies to extract raw datasets and perform an Individual Participant Data meta-analysis (IPDMA). Inclusion criteria were: psychopathology of individuals with schizophrenia spectrum disorders assessed by the Positive and Negative Syndrome Scale (PANSS); cannabis-users had to either have a diagnosis of cannabis use disorder or use cannabis at least twice a week. The main outcomes were the PANSS subscores extracted via the 3-factor (positive, negative and general) and 5-factor (positive, negative, disorganization, depression, excitement) structures. Preregistration is accessible via Prospero: ID CRD42022329172.Findings Among the 1149 identified studies, 65 were eligible and 21 datasets were shared, totaling 3677 IPD and 3053 complete cases. The adjusted multivariate analysis revealed that relative to non-use, cannabis use was associated with higher severity of positive dimension (3-factor: Adjusted Mean Difference, aMD = 0.34, 95% Confidence Interval, CI = [0.03; 0.66]; 5-factor: aMD = 0.38, 95% CI = [0.08; 0.63]), lower severity of negative dimension (3-factor: aMD = -0.49, 95% CI [-0.90; -0.09]; 5-factor: aMD = -0.50, 95% CI = [-0.91; -0.08]), higher severity of excitement dimension (aMD = 0.16, 95% CI = [0.03; 0.28]). No association was found between cannabis use and disorganization (aMD = -0.13, 95% CI = [-0.42; 0.17]) or depression (aMD = -0.14, 95% CI = [-0.34; 0.06]).Interpretation No causal relationship can be inferred from the current results. The findings could be in favor of both a detrimental and beneficial effect of cannabis on positive and negative symptoms, respectively. Longitudinal designs are needed to understand the role of cannabis is this association. The reported effect sizes are small and CIs are wide, the interpretation of findings should be taken with caution.ELSEVIER2023info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://fsjd.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=24623EClinicalMedicineISSN: 25895370reponame:r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déuinstname:Fundació Sant Joan de DéuInglésinfo:eu-repo/semantics/openAccessoai:fsjd.fundanetsuite.com:p246232026-05-27T12:37:41Z
dc.title.none.fl_str_mv Association between cannabis use and symptom dimensions in schizophrenia spectrum disorders: an individual participant data meta on 3053 individuals
title Association between cannabis use and symptom dimensions in schizophrenia spectrum disorders: an individual participant data meta on 3053 individuals
spellingShingle Association between cannabis use and symptom dimensions in schizophrenia spectrum disorders: an individual participant data meta on 3053 individuals
Argote M
Cannabis
Schizophrenia
PANSS
Individual participant data
Symptom dimensions
Meta-analysis
title_short Association between cannabis use and symptom dimensions in schizophrenia spectrum disorders: an individual participant data meta on 3053 individuals
title_full Association between cannabis use and symptom dimensions in schizophrenia spectrum disorders: an individual participant data meta on 3053 individuals
title_fullStr Association between cannabis use and symptom dimensions in schizophrenia spectrum disorders: an individual participant data meta on 3053 individuals
title_full_unstemmed Association between cannabis use and symptom dimensions in schizophrenia spectrum disorders: an individual participant data meta on 3053 individuals
title_sort Association between cannabis use and symptom dimensions in schizophrenia spectrum disorders: an individual participant data meta on 3053 individuals
dc.creator.none.fl_str_mv Argote M
Sescousse G
Brunelin J
Baudin G
Schaub MP
Rabin R
Schnell T
Ringen PA
Andreassen OA
Addington JM
Brambilla P
Delvecchio G
Bechdolf A
Wobrock T
Schneider-Axmann T
Herzig D
Mohr C
Vila-Badia R
Rodie JU
Mallet J
Ricci V
Martinotti G
Knížková K
Rodriguez M
Cookey J
Tibbo P
Scheffler F
Asmal L
Garcia-Rizo C
Amoretti S
Huber C
Thibeau H
Kline E
Fakra E
Jardri R
Nourredine M
Rolland B
author Argote M
author_facet Argote M
Sescousse G
Brunelin J
Baudin G
Schaub MP
Rabin R
Schnell T
Ringen PA
Andreassen OA
Addington JM
Brambilla P
Delvecchio G
Bechdolf A
Wobrock T
Schneider-Axmann T
Herzig D
Mohr C
Vila-Badia R
Rodie JU
Mallet J
Ricci V
Martinotti G
Knížková K
Rodriguez M
Cookey J
Tibbo P
Scheffler F
Asmal L
Garcia-Rizo C
Amoretti S
Huber C
Thibeau H
Kline E
Fakra E
Jardri R
Nourredine M
Rolland B
author_role author
author2 Sescousse G
Brunelin J
Baudin G
Schaub MP
Rabin R
Schnell T
Ringen PA
Andreassen OA
Addington JM
Brambilla P
Delvecchio G
Bechdolf A
Wobrock T
Schneider-Axmann T
Herzig D
Mohr C
Vila-Badia R
Rodie JU
Mallet J
Ricci V
Martinotti G
Knížková K
Rodriguez M
Cookey J
Tibbo P
Scheffler F
Asmal L
Garcia-Rizo C
Amoretti S
Huber C
Thibeau H
Kline E
Fakra E
Jardri R
Nourredine M
Rolland B
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Cannabis
Schizophrenia
PANSS
Individual participant data
Symptom dimensions
Meta-analysis
topic Cannabis
Schizophrenia
PANSS
Individual participant data
Symptom dimensions
Meta-analysis
description Background The association between cannabis use and positive symptoms in schizophrenia spectrum disorders is well documented, especially via meta-analyses. Yet, findings are inconsistent regarding negative symptoms, while other dimensions such as disorganization, depression, and excitement, have not been investigated. In addition, meta-analyses use aggregated data discarding important confounding variables which is a source of bias.Methods PubMed, ScienceDirect and PsycINFO were used to search for publications from inception to September 27, 2022. We contacted the authors of relevant studies to extract raw datasets and perform an Individual Participant Data meta-analysis (IPDMA). Inclusion criteria were: psychopathology of individuals with schizophrenia spectrum disorders assessed by the Positive and Negative Syndrome Scale (PANSS); cannabis-users had to either have a diagnosis of cannabis use disorder or use cannabis at least twice a week. The main outcomes were the PANSS subscores extracted via the 3-factor (positive, negative and general) and 5-factor (positive, negative, disorganization, depression, excitement) structures. Preregistration is accessible via Prospero: ID CRD42022329172.Findings Among the 1149 identified studies, 65 were eligible and 21 datasets were shared, totaling 3677 IPD and 3053 complete cases. The adjusted multivariate analysis revealed that relative to non-use, cannabis use was associated with higher severity of positive dimension (3-factor: Adjusted Mean Difference, aMD = 0.34, 95% Confidence Interval, CI = [0.03; 0.66]; 5-factor: aMD = 0.38, 95% CI = [0.08; 0.63]), lower severity of negative dimension (3-factor: aMD = -0.49, 95% CI [-0.90; -0.09]; 5-factor: aMD = -0.50, 95% CI = [-0.91; -0.08]), higher severity of excitement dimension (aMD = 0.16, 95% CI = [0.03; 0.28]). No association was found between cannabis use and disorganization (aMD = -0.13, 95% CI = [-0.42; 0.17]) or depression (aMD = -0.14, 95% CI = [-0.34; 0.06]).Interpretation No causal relationship can be inferred from the current results. The findings could be in favor of both a detrimental and beneficial effect of cannabis on positive and negative symptoms, respectively. Longitudinal designs are needed to understand the role of cannabis is this association. The reported effect sizes are small and CIs are wide, the interpretation of findings should be taken with caution.
publishDate 2023
dc.date.none.fl_str_mv 2023
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://fsjd.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=24623
url https://fsjd.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=24623
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv ELSEVIER
publisher.none.fl_str_mv ELSEVIER
dc.source.none.fl_str_mv EClinicalMedicine
ISSN: 25895370
reponame:r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
instname:Fundació Sant Joan de Déu
instname_str Fundació Sant Joan de Déu
reponame_str r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
collection r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869403263625854976
score 15,198674

Similares en LA Referencia